SIRT1 and Hepatic fibrosis: A rising body of research has indicated that Sirt1 exhibits the potential to hinder necroptosis in diverse disease models, encompassing cancer (Carafa et al., 2018), liver fibrosis (Sun et al., 2022), nephropathy (Liu Z et al., 2022), and others.